Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
AI can call the shots on drug making because it 'doesn't have a career at stake,' major pharma CEO says
"And we're not used to having somebody without a career at stake in the room at a senior level," said Hudson.
J.P. Morgan Sticks to Their Hold Rating for Bayer (0P6S)
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of ...
Thailand Business News23h
India Remains a Magnet for Pharmaceutical Investments Despite Regulatory Challenges
Bayer's expanded therapies and strategic collaborations in India aim to drive pharmaceutical growth amidst regulatory challenges and pricing pressures.